What is the current stock price of Eloxx Pharmaceuticals, Inc. (ELOX)?

As of the latest market data, Eloxx Pharmaceuticals, Inc. (ELOX) is trading at $0.08. The stock has seen a gain of 17.75% today.

Does Eloxx Pharmaceuticals, Inc. (ELOX) pay a dividend?

Based on current data, Eloxx Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Eloxx Pharmaceuticals, Inc.?

The current market capitalization of Eloxx Pharmaceuticals, Inc. (ELOX) is approximately unavailable.

ELOX

Eloxx Pharmaceuticals, Inc.·Healthcare

0.08

17.746%(+0.01)

Market Closed

0.09

3.110%(+0.00)

After Hours

Last Updated: — ET

52W L: $0.0052W H: $0.75

ELOX NEWS

defenseworld.net

Jan 26

Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)

Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Profitability This table compares Eloxx Pharmaceuticals and Prime

defenseworld.net

Jan 22

Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)

Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Profitability This table compares Eloxx Pharmaceuticals and Finch Therapeutics Group's

defenseworld.net

Jan 22

Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Eloxx Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals"s revenue, earnings per share and

Company Profile

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1999-04-26

Beta

-24.60

Websitewww.eloxxpharma.com↗